Abstract | OBJECTIVE: Two randomised, double-blind, double-dummy trials evaluated the efficacy and tolerability of meloxicam compared with placebo or diclofenac in patients with acute sciatica. SUBJECTS: TREATMENT AND METHODS: RESULTS:
Meloxicam 7.5 mg and 15 mg significantly improved overall pain between baseline and day 7 (p < 0.05) compared with placebo. Furthermore, both meloxicam doses showed similar improvements on all primary and secondary efficacy endpoints compared with diclofenac 150 mg. No significant differences in tolerability were observed between any of the treatment groups in either study. CONCLUSIONS:
|
Authors | R L Dreiser, J M Le Parc, P Vélicitat, P L Lleu |
Journal | Inflammation research : official journal of the European Histamine Research Society ... [et al.]
(Inflamm Res)
Vol. 50 Suppl 1
Pg. S17-23
(Mar 2001)
ISSN: 1023-3830 [Print] Switzerland |
PMID | 11339516
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Anti-Inflammatory Agents, Non-Steroidal
- Cyclooxygenase Inhibitors
- Thiazines
- Thiazoles
- Diclofenac
- Meloxicam
|
Topics |
- Acute Disease
- Administration, Oral
- Adult
- Aged
- Anti-Inflammatory Agents, Non-Steroidal
(therapeutic use)
- Cyclooxygenase Inhibitors
(therapeutic use)
- Diclofenac
(adverse effects, therapeutic use)
- Double-Blind Method
- Female
- Humans
- Male
- Meloxicam
- Middle Aged
- Sciatica
(drug therapy)
- Thiazines
(administration & dosage, adverse effects, therapeutic use)
- Thiazoles
(administration & dosage, adverse effects, therapeutic use)
|